Athanasios Karampeazis

Pemetrexed versus erlotinib in pretreated patients with advanced non–small cell lung cancer: A Hellenic Oncology Research Group (HORG) randomized phase 3 study

Athanasios Karampeazis, Alexandra Voutsina, John Souglakos et al. · Cancer · 2013 · 112 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Three- versus six-month adjuvant FOLFOX or CAPOX for high-risk stage II and stage III colon cancer patients: the efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) project

John Souglakos, Ioannis Boukovinas, Stylianos Kakolyris et al. · Annals of Oncology · 2019 · 47 citations · Full text

Medicine, Oncology, Chemotherapy +12

Pemetrexed (MTA) compared with erlotinib (ERL) in pretreated patients with advanced non-small cell lung cancer (NSCLC): Results of a randomized phase III Hellenic Oncology Research Group trial.

L. Vamvakas, Sofia Agelaki, Athanasios Karampeazis et al. · Journal of Clinical Oncology · 2010 · 37 citations

Medicine, Oncology, Pharmacology +11

Clinical outcome of elderly patients with metastatic colorectal cancer treated with FOLFOXIRI versus FOLFIRI: Subgroup analysis of a randomized phase III trial from the Hellenic Oncology Research Group (HORG)

L. Vamvakas, A. Athanasiadis, Athanasios Karampeazis et al. · Critical Reviews in Oncology/Hematology · 2009 · 33 citations

Medicine, Geriatric Medicine, Oncology +15

Docetaxel Vs. Vinorelbine in Elderly Patients With Advanced Non–Small-Cell Lung Cancer: A Hellenic Oncology Research Group Randomized Phase III Study

Athanasios Karampeazis, Lambros Vamvakas, Athina Agelidou et al. · Clinical Lung Cancer · 2011 · 24 citations

Medicine, Oncology, Pharmacology +6